一分钟看懂
这是一项关于尿路上皮癌的III 期研究，登记的药物或干预包括Nadofaragene Firadenovec，当前状态为招募中。登记地点显示中国Mobile、Phoenix、Tucson、Little Rock等城市有研究中心记录。是否仍有名额以及是否值得进一步询问，需要向研究中心确认。
药物或干预
Nadofaragene Firadenovec · III 期
登记条件中文摘要
年龄范围：18岁及以上
登记的基本范围为不限性别，年龄18岁及以上；以下仅摘录8项专业入选条件，需结合英文原文并由研究团队确认。
登记记录列出8项主要排除条件，具体医学含义需结合英文原文并由研究团队确认。
中国哪些地方有记录
以下地点来自登记信息，不代表此刻仍有名额；请向研究中心确认最新情况。
- University of South Alabama (USA) Health System - USACM · Mobile
- Urology Associates of Mobile · Mobile
- Mayo Clinic Arizona · Phoenix
- Center for Neurosciences · Tucson
- Arkansas Urology, North Little Rock · Little Rock
- Michael G Oefelein, MD Clinical Trials · Bakersfield
- Urology Associates of Central California · Fresno
- American Institute of Research · Los Angeles
- Urology Center of Southern California · Murrieta
- University of California, Irvine · Orange
- Providence Saint John's Cancer Institute · Santa Monica
- Advent Health · Denver
- Medstar Georgetown University Hospital · Washington D.C.
- Mayo Clinic · Jacksonville
- Advanced Urology institute - Pinellas · Largo
- Sarasota Memorial Healthcare System · Sarasota
- Emory University · Atlanta
- NextStage Clinical Research · Lisle
- Blessing Health System · Quincy
- First Urology Research (Jeffersonville) · Jeffersonville
- Urology Center of Iowa Research · Clive
- Wichita Urology Group · Wichita
- University of Kentucky (UK) - Markey Cancer Center · Lexington
- Anne Arundel Urology, PA · Annapolis
- Beth Israel Lahey Health-Beth Israel Deaconess Medical Center (BIDMC) · Boston
- Mayo Clinic - Rochester Minnesota · Rochester
- The Urology Group P.C · Southaven
- Mercy Clinic Oncology and Hematology - David C. Pratt Cancer Center · Creve Coeur
- Specialty Clinical Research of St. Louis · St Louis
- Adult and Pediatric Urology P.C. · Omaha
入选条件原文摘录
以下为摘录，请打开原始登记查看完整入排标准。
- * Diagnosed with intermediate risk non-muscle invasive bladder cancer (IR NMIBC) as defined by American Urological Association (AUA)/Society of Urologic Oncology \[SUO\] Guideline (2020)
- * Has undergone adequate transurethral resection of bladder tumor (TURBT; with or without peri-operative chemotherapy) within 60 days prior to randomization:
- Recurrence within 1 year, low-grade Ta
- Solitary low-grade Ta \>3 cm
- Low-grade Ta, multifocal
- Solitary high-grade Ta, ≤3 cm
- Low-grade T1
- Patients with T1 disease should undergo resection at the base of the lesion and biopsies should contain muscle fibres.
联系前需要确认
请继续确认中心是否启动、疾病分型、既往治疗、检查费用和知情同意安排。
查看登记信息
登记号：NCT06510374；登记信息更新于 2026-10-07；本站同步于 2026-10-08。